More than 100 years later, non-small-cell lung cancer (NSCLC) with activating mutations of the Kirsten rat sarcoma (KRAS) oncogene—despite representing almost one-third of all lung cancer cases—remains a tumor entity for which no fully FDA- or EMA-approved oncogene-targeted therapies exist (for a broader overview of the frequencies of known oncogenic driver events in NSCLC we refer to [2,3,4,5,6]). The gene discussed is KRAS; the disease is neoplasm.